Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine for Microvascular Dysfunction in HCM
NCT03953989Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Oct 2016
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ranolazine in hypertrophic cardiomyopathy (HCM), sponsored by IRCCS Ospedale San Raffaele. Primary endpoints: Myocardial Blood Flow during hyperemia at 4 months, Coronary Flow Reserve at 4 months and 1 more. Started Oct 2016; status: completed.
02
Drugs
ranolazine
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT03953989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03953989.